Kyntra Bio Inc (KYNB)

Currency in USD
6.790
+0.010(+0.15%)
Closed·
6.7900.000(0.00%)
·
Advertisement
Earnings results expected in 11 days
KYNB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.7096.905
52 wk Range
6.32012.600
Key Statistics
Prev. Close
6.78
Open
6.77
Day's Range
6.709-6.905
52 wk Range
6.32-12.6
Volume
5.69K
Average Volume (3m)
18.25K
1-Year Change
-3.4139%
Book Value / Share
-10.82
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KYNB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
39.000
Upside
+474.37%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Kyntra Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 39.000
(+474.37% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Oppenheimer
Buy35.00+415.46%-New Coverage06/07/2026
H.C. Wainwright
Buy43.00+533.28%-Maintain25/09/2025
H.C. Wainwright
Buy43.00+533.28%-Maintain03/09/2025
H.C. Wainwright
Buy43.00+533.28%10.00Maintain08/08/2025

Kyntra Bio Inc Earnings Call Summary for Q2/2025

  • FibroGen reports Q2 2025 EPS of -$1.88, missing forecast of -$0.09; revenue falls short at $1.3M vs $2.88M expected
  • Stock drops 3.9% to $8.71 post-earnings; company valued at $34M market cap, deemed overvalued by InvestingPro analysis
  • Operating costs decrease 72% YoY; R&D expenses down 82%; company extends cash runway to 2028
  • Full-year 2025 revenue guidance set at $6M-$8M; Phase II trial for prostate cancer treatment FG3246 to begin Q3 2025
  • CEO expresses optimism about clinical programs; CFO highlights financial strategies to benefit shareholders
Last Updated: 11/08/2025, 22:46
Read Full Transcript

Earnings

Latest Release
11/05/2026
EPS / Forecast
-3.76 / -0.21
Revenue / Forecast
3.7M / 1.51M
EPS Revisions
Last 90 days

Compare KYNB to Peers and Sector

Metrics to compare
KYNB
Peers
Sector
Relationship
P/E Ratio
−0.5x12.0x−0.3x
PEG Ratio
0.000.160.00
Price/Book
−0.6x3.1x2.6x
Price / LTM Sales
3.7x3.9x2.9x
Upside (Analyst Target)
-96.1%56.7%
Fair Value Upside
Unlock10.5%10.2%Unlock

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Employees
34

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
234.48K5.79%1.59M
Other Institutional Investors
1.20M29.75%8.17M
Public Companies & Retail Investors
2.61M64.45%17.69M
Total
4.05M100.00%27.45M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Armistice Capital LLC9.88%400,0002,712
Armistice Capital Master Fund Ltd.9.88%400,0002,712

People Also Watch

63.86
GSHD
-9.70%
20.37
AMPH
-1.02%
4.450
NUWE
+135.45%
0.9128
BGMS
+3.73%
0.1360
CISS
+2.33%

FAQ

What Is the Kyntra Bio (NASDAQ: KYNB) Share Price Today?

The Kyntra Bio stock price today is 6.790 USD.

What Stock Exchange Does Kyntra Bio (KYNB) Trade On?

Kyntra Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Kyntra Bio?

The stock symbol (also called a 'ticker') for Kyntra Bio is "KYNB."

What Is the Current Kyntra Bio Market Capitalisation?

As of today, Kyntra Bio (NASDAQ: KYNB) market cap is 27.750M USD.

What Is Kyntra Bio's (KYNB) Earnings Per Share (TTM)?

The Kyntra Bio EPS is currently -13.984 (Trailing Twelve Months).

When Is the Next Kyntra Bio Earnings Date?

Kyntra Bio's next earnings report will be released on 10/08/2026.

Is KYNB a Buy or Sell From a Technical Analyst Perspective?

Based on today's Kyntra Bio moving averages and other technical indicators, the daily buy/sell signal for KYNB stock is Strong Sell.

How Many Times Has Kyntra Bio Stock Split?

Kyntra Bio has split 1 times. (See the KYNB stock split history page for full effective split date and price information.)

How Many Employees Does Kyntra Bio Have?

Kyntra Bio has 34 employees, based on their latest Companies House report.

What is the current trading status of Kyntra Bio (NASDAQ: KYNB)?

As of 30/07/2026, Kyntra Bio (KYNB) is trading at a share price of 6.790 USD, with a previous close of 6.780 USD. The stock has fluctuated within a day range of 6.709 USD to 6.905 USD, while its 52-week range spans from 6.320 USD to 12.600 USD.

What Is Kyntra Bio (KYNB) Price Target According to Analysts?

The average 12-month price target for Kyntra Bio is 39.000 USD, with a high estimate of 43 USD and a low estimate of 35 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +474.37% Upside potential.

What Is the KYNB Premarket Price?

KYNB's last pre-market stock price is 6.760 USD. The pre-market share volume is 10.000, and the stock has decreased by -0.020, or -0.290%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.